Transport
Mercy Hospital of Franciscan Sisters INC
Mercy Hospital of Franciscan Sisters INC was paid $1.97M by Medicaid between Jan 2018 and Dec 2024, across 47 billing codes. Its largest line is 99283, emergency room visit (moderate) — 39% of everything it billed.
33Billing provider infoMERCY HOSPITAL OF FRANCISCAN SISTERS INC
OELWEIN, IA 50662
OELWEIN, IA 50662
33aNPI1528009511assigned 06/09/2006
33bProvider typeAmbulance
28Total paid$1.97M
24GClaims25,066
24DCodes billed47
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in Iowa
Rank by total paid#8 of 45
Median peer was paid$85K
This provider vs. median23×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HUBER, TIMOTHY controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,978 | $210K | |
| 2019 | 2,542 | $309K | |
| 2020 | 2,943 | $317K | |
| 2021 | 5,236 | $348K | |
| 2022 | 5,289 | $367K | |
| 2023 | 3,795 | $268K | |
| 2024incomplete | 2,283 | $151K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 39% | 3,169 | 2,750 | $774K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 1,447 | 1,208 | $499K |
| 80053 | Comprehensive metabolic panel | 8.8% | 4,126 | 3,594 | $173K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.3% | 287 | 229 | $104K |
| 87081 | 4.1% | 3,066 | 2,992 | $81K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.2% | 3,026 | 2,550 | $63K |
| 36415 | Collection of venous blood by venipuncture | 2.6% | 4,448 | 3,854 | $51K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 282 | 277 | $35K |
| 86140 | 1.2% | 998 | 880 | $23K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 558 | 513 | $23K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 146 | 137 | $22K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 183 | 145 | $21K |
35 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 110 | $12K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 423 | $11K |
| 80061 | Lipid panel | <1% | 169 | $10K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 169 | $9K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 160 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 256 | $7K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 99 | $5K |
| 85027 | <1% | 264 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 52 | $3K |
| 84484 | <1% | 280 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 51 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 176 | $3K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 73 | $2K |
| 87070 | <1% | 60 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 16 | $2K |
| 80305 | <1% | 64 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 206 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 151 | $1K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 17 | $1K |
| 83690 | <1% | 56 | $1K | |
| 82550 | <1% | 70 | $973.69 | |
| 87400 | <1% | 14 | $938.42 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13 | $869.82 |
| 71045 | Radiologic examination, chest; single view | <1% | 25 | $796.84 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12 | $587.22 |
| 83605 | <1% | 18 | $569.91 | |
| 85610 | <1% | 77 | $522.12 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 29 | $439.56 |
| 81001 | <1% | 41 | $371.29 | |
| 81003 | <1% | 80 | $365.44 | |
| 83735 | <1% | 39 | $326.26 | |
| 94664 | <1% | 16 | $298.70 | |
| 85007 | <1% | 14 | $244.14 | |
| 85379 | <1% | 14 | $209.24 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16 | $126.01 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHUBER, TIMOTHY (CONTROLLER)
| Provider | Location | Paid |
|---|---|---|
| Covenant Medical Center INC | Waterloo, IA | $63.08M |
| Covenant Medical Center INC | Waterloo, IA | $22.00M |
| Covenant Medical Center INC | Waterloo, IA | $2.06M |
| Covenant Medical Center INC | Waterloo, IA | $618K |
| Sartori Memorial Hospital INC | Cedar Falls, IA | $439K |
| Sartori Memorial Hospital INC | Cedar Falls, IA | $313K |
| Covenant Medical Center INC | Arlington, IA | $225K |
| Mercy Hospital of Franciscan Sisters INC | Oelwein, IA | $139K |
| Sartori Memorial Hospital INC | Cedar Falls, IA | $117K |
| Covenant Medical Center INC | Waterloo, IA | $99K |
| Mercy Hospital of Franciscan Sisters INC | Oelwein, IA | $15K |
| Covenant Medical Center INC | Waterloo, IA | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.